Interstitial pneumonitis associated with infliximab therapy in a rheumatoid arthritis patient.
- Author:
In Seol YOO
1
;
Ju Kyoung SONG
Author Information
1. Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
- Publication Type:Case Report
- Keywords:
Rheumatoid arthritis;
Interstitial pneumonitis;
Tumor necrosis factor-alpha inhibitor;
Infliximab
- MeSH:
Aged;
Antibodies, Monoclonal;
Arthritis, Psoriatic;
Arthritis, Rheumatoid;
Autoimmune Diseases;
Biological Agents;
Heart Failure;
Humans;
Lung Diseases, Interstitial;
Spondylitis, Ankylosing;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Korean Journal of Medicine
2010;79(2):215-218
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Tumor necrosis factor (TNF)-alpha inhibitors are well-established biological agents for the treatment of a wide variety of chronic autoimmune diseases and inflammatory conditions, including rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis. Although these drugs have been noted to have good safety profiles, some important side effects, including infection, injection site reactions, lupus-like syndrome, congestive heart failure, and malignancies have been reported. Therefore, utilization of TNF-alpha inhibitors demands caution. Interstitial pneumonitis is a very rare complication of TNF-alpha inhibitors. We report here a 71-year-old man with RA who developed interstitial pneumonitis after the third infusion of infliximab.
